Premium
High levels of hepatocyte growth factor/scatter factor in diffuse‐type bronchioloalveolar cell carcinoma
Author(s) -
Yamashita Junichi,
Ogawa Michio,
Nakano Shogo,
Okabe Kazutoshi,
Abe Michio,
Iwasaki Akinori,
Kuwahara Motohisa,
Yoshinaga Yasuteru,
Shirakusa Takayuki
Publication year - 1998
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/(sici)1097-0142(19981115)83:10<2091::aid-cncr7>3.0.co;2-e
Subject(s) - adenocarcinoma , hepatocyte growth factor , pathology , carcinoma , medicine , large cell , immunohistochemistry , c met , cell , cancer research , cancer , biology , receptor , genetics
BACKGROUND Hepatocyte growth factor/scatter factor (HGF/SF) is a potent mitogen for various neoplastic cells, including neoplastic bronchial epithelia. METHODS Immunoreactive hepatocyte growth factor/scatter factor (HGF/SF) was measured in extracts prepared from 129 nonsmall cell lung carcinoma (NSCLC) specimens, using an enzyme‐linked immunosorbent assay. These specimens represented 5 cases of solitary/localized bronchioloalveolar cell carcinoma (BAC), 4 cases of diffuse/infiltrative BAC, 90 cases of non‐BAC adenocarcinoma, 25 cases of squamous cell carcinoma, and 5 cases of large cell carcinoma. RESULTS The mean concentration of immunoreactive HGF/SF was more than 19‐fold higher in tissue extracts from diffuse‐type BAC (265.0 ± 110.2 ng/100 mg protein) than in those from solitary‐type BAC (13.9 ± 15.9, P < 0.005), non‐BAC adenocarcinoma (13.8 ± 14.9, P < 0.001), squamous cell carcinoma (13.2 ± 14.4, P < 0.001), or large cell carcinoma (11.2 ± 6.5, P < 0.005). When immunohistochemical staining for HGF/SF was performed, intense HGF/SF staining was uniformly observed in diffuse‐type BAC tumor cells, but not in solitary‐type BAC. CONCLUSIONS Although BAC is included as a subtype of adenocarcinoma in the World Health Organization classification, diffuse‐type BAC should be considered a distinct biologic entity, at least in terms of HGF/SF expression, from solitary‐type BAC or non‐BAC adenocarcinoma. In addition, the solitary and diffuse forms of BAC are known to be associated with different prognoses; for the latter, the prognosis is much poorer than for the former. The results of this study may at least partly explain this difference in prognosis. Cancer 1998;83:2091‐2098. © 1998 American Cancer Society.